Jacobs Levy Equity Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-102,409	Closed	-$298K	–	1140
2021 Q3	$298K	Buy	+102,409	New	+$340K	﹤0.01%	939
2021 Q1	–	Sell	-255,202	Closed	-$4.9M	–	1161
2020 Q4	$4.9M	Buy	255,202 +178,169	+231%	+$2.75M	0.04%	403
2020 Q3	$1.03M	Buy	77,033 +23,129	+43%	+$655K	0.01%	658
2020 Q2	$2.28M	Buy	53,904 +28,646	+113%	+$927K	0.02%	507
2020 Q1	$697K	Buy	+25,258	New	+$736K	0.01%	700
2019 Q3	–	Sell	-37,923	Closed	-$1.39M	–	1031
2019 Q2	$1.39M	Sell	37,923 -2,194	-5%	-$52.6K	0.02%	583
2019 Q1	$887K	Buy	+40,117	New	+$701K	0.01%	685

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Jacobs Levy Equity Management's ODT Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 102,409 shares — an estimated $298K sold.

Jacobs Levy Equity Management first reported a position in ODT in Q1 2019 and held it in 7 quarters. The position peaked at $4.9M in Q4 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

Jacobs Levy Equity Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Jacobs Levy Equity Management sold 102,409 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $298K.
Jacobs Levy Equity Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2019 and held it in 7 quarters.
Jacobs Levy Equity Management's Odonate Therapeutics, Inc. Common Stock position peaked at $4.9M in Q4 2020.
50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.